



UCB
News

Acquisition of own shares

Brussels (Belgium), 1 April 2016 – 18:00 (CET) – regulated information

In application of article 207 of the Royal Decree executing the Companies Code, UCB SA/NV announces that on March 30, 2016, UCB SA/NV and UCB Celltech, UK branch of UCB Pharma SA bought 36 945 and 7 895 UCB shares respectively (settlement date April 1, 2016), OTC from an affiliate, at a price of € 68.1078 per share, in view of deliveries of shares to employees within the framework of the Long Term Incentive Program of the UCB Group.

The highest independent bid price on Euronext Brussels on 30 March 2016 was €69.40.

On April 1, 2016, after settlement of the above mentioned transactions, UCB SA/NV owns 3,842,932 UCB shares, which represent 1.97 % of the total number of shares issued by the company (194,505,658).

An updated overview of the UCB SA/NV large shareholdings will be included in the corporate governance charter of UCB SA/NV, which is available on its website

For further information

Investor Relations

Antje Witte,
Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 700 people in approximately 40 countries, the company generated revenue of € 3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news